TruePrime™ LB address the current liquid biopsy sensitivity and specificity issues by utilizing the adapted amplification of cancer specific large fragment cfDNA based on primer-free TruePrime™ technology based on the combination of the enzyme TthPrimPol and Phi29 DNA polymerase.
TruePrime™ mediated circulating tumor DNA (ctDNA) amplification specifically amplifies and selects the larger, more cancer-specific, DNA fragment size population from human plasma. Consequently, TruePrime™ LB provides a method for assessing cancer genome information from all patients, regardless of tumor burden, with superior sensitivity and specificity, reliable at 100 pg of total cfDNA while preserving the single nucleotide variants (SNVs) and SNV frequencies across different sequencing technologies and allowing the amplification of cfDNA to levels than permit sequencing.
TruePrime™ LB provides a screening method for de-novo detection of cancer or reoccurrence of cancer based on a threshold of amplified DNA obtainable within a certain reaction time frame. The method of detecting cancer is further enhanced by providing a test for the presence of human DNA derived from larger fragments based on a panel of PCR primers, for example the CovCheck™ kit, which SYGNIS launched worldwide in October this year.
